Results 211 to 220 of about 260,272 (304)

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou   +12 more
wiley   +1 more source

Carboranyl‐Curcuminoids for the Neutron Capture‐Based Treatment of Amyloid Aggregates in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
The 10B‐enriched monocarbonyl analog of curcumin (BMAC) 10B‐9 enables site‐specific Boron Neutron Capture Therapy (BNCT) on amyloid‐β (Aβ) fibrils. Neutron irradiation induces histidine oxidation and fibril destabilization, as revealed by 1H‐NMR and FESEM analyses.
Sebastiano Micocci   +13 more
wiley   +1 more source

Determination of HE4 in pleural fluid and ratio: considerations and diagnostic performance for malignant pleural effusion. [PDF]

open access: yesAdv Lab Med
Nuez-Zaragoza E   +15 more
europepmc   +1 more source

Epithelial TRIM27 Inhibits Intestinal Inflammation in Ulcerative Colitis by the USP7/TRIM27‐IKK Double Negative‐Feedback

open access: yesAdvanced Science, EarlyView.
ABSTRACT The E3 ubiquitin ligase tripartite motif 27 (TRIM27) is a negative regulator of NF‐κB activation and the innate immune response, and TRIM27 deficiency significantly impairs dextran sulfate sodium (DSS)‐induced colitis. The function of TRIM27 in intestinal epithelial cells (IECs), the mechanism by which TRIM27 inhibits the NF‐κB pathway and its
Weimin Xu   +10 more
wiley   +1 more source

Value of Myocardial Strain in Assessing Cardiac Masses: A Case Report. [PDF]

open access: yesMethodist Debakey Cardiovasc J
West J   +8 more
europepmc   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

Short- and Long-Term Outcomes of Pericarditis, Myocarditis, and Myopericarditis in Patients With Malignancy on Immune Checkpoint Inhibitors. [PDF]

open access: yesJ Am Heart Assoc
Agrawal A   +12 more
europepmc   +1 more source

Developmentally Inspired Bioprinting of Nascent Multicellular Human Heart Tissue Through in Situ Differentiation and Morphogenesis of iPSCs

open access: yesAdvanced Science, EarlyView.
A developmentally inspired bioprinting approach enables the fabrication of pluripotent tissues that undergo shape‐morphing and in situ cardiac lineage specification. This method employs embedded bioprinting to deposit iPSCs within soft granular hydrogels to create pluripotent tissue constructs that undergo cell‐mediated shape morphogenesis.
Ankita Pramanick   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy